A mathematical method was developed to study the skin penetration of volatile organic compounds (VOCs) after exposure to a high dose of the substance. While closed-form solutions exist to describe the diffusion and evaporation from small amounts, numerical approaches are often implemented to predict dermal transport involving large doses. This work offers a Laplace transform-based method to estimate the time constant and dynamic and steady-state behaviors. First, the process was divided into two stages, separated by the time it took for excess chemicals to be depleted from the skin surface. Series solutions were written for the percutaneous VOC concentration, absorption and evaporation in the first stage. Application of Laplace transform methods yielded transient profiles after the compound dissipated from the surface of the stratum corneum. In addition, the procedure facilitated the calculation of the time constant and steady-state values. The method was validated using benchtop and fume hood experiments conducted with N,N-diethyl-3-methylbenzamide (DEET) and air velocities of 0.165 m/s and 0.72 m/s, respectively. The increase in the flow rate decreased the total amount of VOC absorbed and reduced the period required for the surface fluid to disappear.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mbs.2022.108889 | DOI Listing |
Vaccine
January 2025
Zhengding County Center for Disease Control and Prevention, Shijiazhuang 050800, China. Electronic address:
To evaluate the long-term efficacy and anamnestic response of Chinese hamster ovary (CHO) cell-derived hepatitis B vaccine (CHO-HepB) after 18-20 years, a cross-sectional survey was conducted in seven communities in Zhengding County at the end of 2017. The birth cohort 1997-1999 vaccinated primarily with three doses of CHO-HepB were enrolled in the survey. The HBV serological markers were quantified using the Chemiluminescence method.
View Article and Find Full Text PDFInt J Med Inform
December 2024
Department of Health Science and Technology, Aalborg University, Selma Lagerløfs Vej 249, 9260 Gistrup, Denmark; Data Science, Novo Nordisk A/S, Søborg, Denmark. Electronic address:
Background And Aim: The progressive nature of type 2 diabetes often, in time, necessitates basal insulin therapy to achieve glycemic targets. However, despite standardized titration algorithms, many people remain poorly controlled after initiating insulin therapy, leading to suboptimal glycemic control and complications. Both healthcare professionals and people with type 2 diabetes have expressed the need for novel tools to aid in this process.
View Article and Find Full Text PDFMol Cancer Ther
December 2024
OBI Pharma, Inc., Taipei, Taiwan.
Trophoblast cell surface antigen 2 (TROP2) is highly expressed in multiple cancers relative to normal tissues, supporting its role as a target for cancer therapy. OBI-992 is an antibody-drug conjugate (ADC) derived from a novel TROP2-targeted antibody linked to the topoisomerase 1 (TOP1) inhibitor exatecan via an enzyme-cleavable hydrophilic linker, with a drug-antibody ratio of 4. This study evaluated and compared the antitumor activity of OBI-992 with that of benchmark TROP2-targeted ADCs datopotamab deruxtecan (Dato-DXd) and sacituzumab govitecan (SG) in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
School of Biomedical Engineering, ShanghaiTech University, Shanghai, China.
Background: About 50-90% people with dementia would develop behavioral disturbances, namely, behavioral and psychological symptoms of dementia (BPSD). Antipsychotic medications are widely used to control severe BPSD symptoms which suffers serious safety risks. It is challenge for individualized precise prediction of antipsychotic drug doses.
View Article and Find Full Text PDFBackground: Drug delivery to the central nervous system has long been hindered by the restrictive properties of the blood-brain barrier (BBB). Recent advances have highlighted the ability of certain antibody "shuttles'' to traverse the BBB and enhance the delivery of diverse therapeutic payloads. However the true potential of this approach remains underexplored and is limited by traditional in vitro screening platforms that fail to capture the complexities of in vivo biology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!